Companies provide screening, prevention, and step-down care to the NHS
FibriCheck enables mobile heart rhythm monitoring with medical-grade accuracy and has been used by more than 2,000 clinicians and hospitals in 43 countries worldwide
Inhealthcare has partnered with FibriCheck to help the NHS combat cardiovascular disease in the UK.
The collaboration between the companies aims to save lives, reduce health inequalities, and ease pressure on the NHS through the scaling up of preventative checks.
Cardiovascular disease affects seven million people and is a major cause of disability and death, especially among disadvantaged communities.
Inhealthcare and FibriCheck will now offer NHS organisations the ability to monitor heart health across integrated care systems and transform detection and condition management for people with atrial fibrillation, high blood pressure, and high cholesterol, the main causes of the disease.
Large numbers of people are living with undiagnosed or under-treated conditions, putting them at risk of grave consequences such as heart attack, stroke, and dementia as well as diabetes, cancer, and Alzheimer’s.
This is another excellent example of how health tech companies with innovative and complementary services can come together to confront the challenges facing the NHS and the nation as a whole
And, according to The King’s Fund, people living in the most-deprived areas are four times more likely to die prematurely from cardiovascular disease than those living in the least-deprived areas.
The NHS Long Term Plan identifies cardiovascular disease as a clinical priority and the single-biggest opportunity to save lives.
Inhealthcare and FibriCheck have joined forces to tackle cardiovascular disease, which costs the health system an estimated £7.4 billion and the wider economy £15.8billion every year, despite being largely preventable through early intervention and management.
Inhealthcare has worked with the NHS for more than a decade and has developed more than 100 clinically-designed digital health services, which have been used by three million patients across the UK.
FibriCheck enables mobile heart rhythm monitoring with medical-grade accuracy and has been used by more than 2,000 clinicians and hospitals in 43 countries worldwide.
Our partnership with FibriCheck gives integrated care systems the ability to detect and manage risk factors in their populations and reduce avoidable deaths and disease
FibriCheck users are empowered to measure their own heart rhythm by placing a finger on the camera of their smartphone, which captures valuable data about their cardiovascular system.
All measurements are analysed by a medically-certified, AI-powered algorithm and the results are immediately available and can be shared easily with the involved physician.
The FibriCheck app can be used on its own, but can also be fully integrated into partner platforms or applications, which allows customised care pathways that streamline clinical care and drive cost efficiency.
Inhealthcare users can also share their readings remotely with healthcare systems via a choice of inclusive communication channels. And, if readings fall out of range, alerts are generated and clinicians intervene as necessary with medical treatment and advice.
Bryn Sage, chief executive of Inhealthcare, said: “Cardiovascular disease is a ticking time bomb and a major cause of morbidity, disability and mortality in the UK, despite being largely preventable.
“Our partnership with FibriCheck gives integrated care systems the ability to detect and manage risk factors in their populations and reduce avoidable deaths and disease and we are excited at our potential to improve heart health at scale and ease pressure on the NHS and wider economy.
“This is another excellent example of how health tech companies with innovative and complementary services can come together to confront the challenges facing the NHS and the nation as a whole.”